While the news of the BARDA contract drove a surge in T2's stock price, it was last month's NTAP decision that has company officials and analysts encouraged.
OncoCyte provided additional details about the history of the Razor test, its timeline for making it commercially available, and plans for a follow-on study.
The health technology firm is proposing a new software solution that would standardize coding in genetic testing, but a more predictable system would also narrow variability in test pricing.
The team analyzed multigene panel test data from Ambry Genetics for 165,000 individuals, focusing on hereditary cancer risk related to 32 genes in six cancer types.
The firm did not disclose the size of the funding, which is helping it build on its Centrellis Health Intelligence Platform and move to whole-exome sequencing.
The immune sequencing firm is working on kit-ifying its two existing tests, as well as developing a second clinical test and expanding the label for clonoSeq.
